- On 27 June 2026, Syndax Pharmaceuticals, Inc. was removed from multiple Russell value benchmarks, including the Russell 2000 Value, 2500 Value, Small Cap Comp Value, 3000E Value, and 3000 Value Indexes.
- This broad index removal can matter for investors because it may trigger benchmark-driven portfolio rebalancing, altering who holds the stock and how it trades.
- We’ll now examine how Syndax’s removal from several Russell value indexes could reshape its investment narrative and investor positioning.
The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 15 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.
Syndax Pharmaceuticals Investment Narrative Recap
To own Syndax today, you need to believe that Revuforj and Niktimvo can grow into durable oncology franchises despite the company still posting sizable net losses. The broad removal from multiple Russell value indexes mainly affects who owns the stock rather than its near term clinical or regulatory path, so it does not materially change the key short term catalyst around Revuforj’s ongoing label expansion or the main risk of concentrated dependence on just two commercial assets.
In this context, the June 11 publication of Phase 1/2 SAVE trial data for Revuforj in relapsed or refractory AML is particularly relevant. While index removal may shift some benchmark driven ownership, the SAVE regimen data speak directly to the core catalyst: strengthening the clinical case for Revuforj in combination settings that could support future expansion efforts, while also highlighting safety considerations that sit at the heart of the biggest current risk to the story.
Yet behind the clinical promise, investors should also be aware that...
Read the full narrative on Syndax Pharmaceuticals (it's free!)
Syndax Pharmaceuticals' narrative projects $748.0 million revenue and $110.2 million earnings by 2029. This requires 63.1% yearly revenue growth and a $395.6 million earnings increase from -$285.4 million today.
Uncover how Syndax Pharmaceuticals' forecasts yield a $39.50 fair value, a 70% upside to its current price.
Exploring Other Perspectives
Compared with the consensus view, the most pessimistic analysts were already cautious, assuming about US$550.7 million revenue and only US$81.2 million earnings by 2029, so this index removal could reinforce their concern about concentration risk and execution, and you may want to weigh how such differing expectations might evolve from here.
Explore 5 other fair value estimates on Syndax Pharmaceuticals - why the stock might be worth over 7x more than the current price!
Reach Your Own Conclusion
Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.
- A great starting point for your Syndax Pharmaceuticals research is our analysis highlighting 2 key rewards that could impact your investment decision.
- Our free Syndax Pharmaceuticals research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Syndax Pharmaceuticals' overall financial health at a glance.
Ready For A Different Approach?
Right now could be the best entry point. These picks are fresh from our daily scans. Don't delay:
- AI is about to change healthcare. These 40 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
- Find 45 companies with promising cash flow potential yet trading below their fair value.
- Rare earth metals are the new gold rush. Find out which 31 stocks are leading the charge.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com